cemiplimab
Libtayo (cemiplimab) is a PD-1 checkpoint inhibitor from Regeneron. By releasing exhausted T cells from the PD-1 brake, it restores immune attack on cancer cells and is used in advanced skin cancers and, with chemotherapy, in non-small cell lung cancer.
This page is based on FDA prescribing information and the EMA medicine record for cemiplimab, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Tumour cells shake hands with T cells through the PD-1 switch, and that handshake tells the immune soldiers to stand down. Cemiplimab puts a glove over the switch, so the handshake never lands, the T cells stay on duty, and they go back to attacking the cancer.
In simple terms
T cells can recognise and kill cancer, but many tumours switch them off through a receptor called PD-1. Cemiplimab is an antibody that blocks PD-1 on T cells, preventing tumour cells from using it as an off-switch. The T cells stay active, multiply and attack the cancer. This approach has proven useful in skin cancers that carry many mutations and in lung cancer.
In depth
Cemiplimab is a fully human IgG4 monoclonal antibody that binds PD-1 with high affinity, blocking interaction with its ligands PD-L1 and PD-L2 without inducing receptor internalisation. This releases PD-1-mediated exhaustion of cytotoxic T lymphocytes, restoring proliferation, cytokine secretion and tumour killing. Cutaneous squamous cell carcinoma and basal cell carcinoma carry high mutational burdens from ultraviolet exposure, generating neoantigens that make them particularly responsive to checkpoint blockade.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How cemiplimab, a fully human IgG4 anti-PD-1 antibody, reactivates T cells
- Tumour cells shake hands with T cells through the PD-1 switch, and that handshake tells the immune soldiers to stand down.
- Cemiplimab puts a glove over the switch, so the handshake never lands, the T cells stay on duty, and they go back to attacking the cancer.
- Cemiplimab is a fully human IgG4 monoclonal antibody that binds PD-1 with high affinity, blocking interaction with its ligands PD-L1 and PD-L2 without inducing receptor internalisation.
- Cutaneous squamous cell carcinoma and basal cell carcinoma carry high mutational burdens from ultraviolet exposure, generating neoantigens that make them particularly responsive to checkpoint blockade.
Target: Programmed cell death receptor 1 (PD-1)
An off-switch on activated T cells; cancers exploit it by presenting PD-L1 to turn T cells off, and blocking the receptor reawakens the anti-tumour response.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
- Adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation
- Treatment of adults with locally advanced or metastatic basal cell carcinoma previously treated with a hedgehog pathway inhibitor, or for whom a hedgehog pathway inhibitor is not appropriate
- With platinum-based chemotherapy, for the first-line treatment of adults with non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations that is locally advanced or metastatic
Approved uses in European Union
EMA- As monotherapy, for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation
- As monotherapy, for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation
Official sources
The statements on this page trace back to these records.
- Libtayo (cemiplimab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: Libtayo (cemiplimab) label
DailyMed, U.S. National Library of Medicine
- U.S. Food and Drug Administration: cemiplimab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: cemiplimab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.